Biomarkers in Alzheimer's Disease

By Tapan Khan, Blanchette Rockefeller Neurosciences Institute, Morgantown WV, USA   Features:

• Presents a comprehensive overview detailing all modalities of Alzheimer’s disease biomarkers
• Written for neuroscience researchers and clinicians studying or treating patients with Alzheimer’s Disease
• Integrates, in each chapter, the molecular/cellular abnormality due to Alzheimer’s disease and the technological advancement of biomarkers techniques

• Dedication
• Foreword
• Preface
• Acknowledgments
• Chapter 1: Introduction to Alzheimer’s Disease Biomarkers
  • Summary
  • 1.1. Historical Background
  • 1.2. Important Events in Alzheimer’s Disease (AD) Research
  • 1.3. Some Facts About Alzheimer’s Disease
  • 1.4. Common Features of Alzheimer’s Disease
  • 1.5. Classification of Alzheimer’s Disease
  • 1.6. Risk Factors for Alzheimer’s Disease
  • 1.7. Definition of a Biomarker
  • 1.8. Biomarkers of Alzheimer’s Disease
  • 1.9. Future Focus: Detecting Preclinical Stages of Alzheimer’s Disease
  • 1.10. Economic Impact of Alzheimer’s Disease Biomarkers
  • 1.11. Conclusions
• Chapter 2: Clinical Diagnosis of Alzheimer’s Disease
  • Summary
  • 2.1. Clinical Diagnosis of Alzheimer’s Disease: Historical Perspective
  • 2.2. Neuropsychological Assessment Tests to Diagnose Alzheimer’s Disease
  • 2.3. Neuropathology at Brain Autopsy to Diagnose Alzheimer’s Disease
  • 2.4. Accuracy of Clinical Diagnosis of Alzheimer’s Disease
  • 2.5. Alzheimer’s Disease-Related Neurological Conditions
  • 2.6. Challenges in Diagnosing Alzheimer’s Disease
  • 2.7. Comprehensive Alzheimer’s Disease Diagnostic Framework
  • 2.8. Conclusions
• Chapter 3: Neuroimaging Biomarkers in Alzheimer’s Disease
  • Summary
  • 3.1. Neuroimaging in Alzheimer’s Disease
  • 3.2. Common Neuroimaging Alzheimer’s Disease Biomarkers and Modalities
  • 3.3. Magnetic Resonance Imaging
  • 3.4. Positron Emission Tomography
  • 3.5. Single-Photon Emission Computed Tomography
  • 3.6. Electroencephalography and Magnetoencephalography in Alzheimer’s Disease
  • 3.7. Discrimination Between Alzheimer’s Disease and Non-Alzheimer’s Disease Dementias by Neuroimaging Biomarkers
  • 3.8. Longitudinal Assessment of Alzheimer’s Disease Neuroimaging Biomarkers
  • 3.9. Early Diagnosis of Alzheimer’s Disease Using Neuroimaging Biomarkers
  • 3.10. Cross-Correlation Between Neuroimaging with Other AD Biomarkers
  • 3.11. Performance of Neuroimaging Biomarkers in Assessing Drug Efficacy in Alzheimer’s Disease Clinical Trials
  • 3.12. Cost of Neuroimaging Biomarkers for Alzheimer’s Disease
  • 3.13. Limitations of Alzheimer’s Disease Neuroimaging Biomarkers
  • 3.14. Conclusions
• Chapter 4: Genetic Biomarkers in Alzheimer’s Disease
  • Summary
  • 4.1. Background
  • 4.2. Approaches to Identifying Genetic Biomarkers in Alzheimer’s Disease
  • 4.3. Early-Onset (Familial) Alzheimer’s Disease Genes
  • 4.4. Recent Advances in Alzheimer’s Disease Genetic Biomarker Research
  • 4.5. Genetic Variability of LOAD Risk Based on Ethnicity
  • 4.6. Genetics Background and Preclinical Alzheimer’s Disease
  • 4.7. Transcriptome Biomarkers in Alzheimer’s Disease
  • 4.8. Micro RNA (miRNA) in Alzheimer’s Disease
  • 4.9. Crosscorrelation of Alzheimer’s Disease Genetic Biomarkers with Other Biomarkers
  • 4.10. Commercial Path for Genetic Biomarker Tests for Alzheimer’s Disease
  • 4.11. Conclusions
• Chapter 5: Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarkers
  • Summary
  • 5.1. Pathophysiology of Aß Production in the Alzheimer’s Disease Brain and Detection in the CSF
  • 5.2. Pathophysiology of Elevated tau and Phosphorylated-tau in the Alzheimer’s Disease Brain and CSF
  • 5.3. Rationale for Using CSF Biomarkers of Neurodegenerative Diseases
  • 5.4. CSF Biomarker Measurement Technologies and Standardization
  • 5.5. Diagnostic Accuracy of CSF Biomarkers in Autopsy- Versus Clinically Validated Alzheimer’s Disease Cohorts
  • 5.6. Discrimination Between Alzheimer’s Disease and Non-Alzheimer’s Disease Dementias by CSF Biomarkers
  • 5.7. Longitudinal Assessment of Alzheimer’s Disease Using CSF Biomarkers
  • 5.8. Limitations of Lumbar Puncture to the Widespread Application of CSF-Based Diagnostic Assays in Alzheimer’s Disease
  • 5.9. Instability of Baseline Aß in CSF
  • 5.10. Interlaboratory Variation in CSF Biomarker Assays
  • 5.11. Performance of CSF Biomarkers in Assessing Drug Efficacy in Alzheimer’s Disease Clinical Trials
  • 5.12. Crosscorrelation of CSF Biomarkers With Other Alzheimer’s Disease Biomarkers Modalities
  • 5.13. Early Diagnosis of Alzheimer’s Disease Using CSF Biomarkers
  • 5.14. Conclusions
• Chapter 6: Peripheral Fluid-Based Biomarkers of Alzheimer’s Disease
  • Summary
  • 6.1. Background
  • 6.2. Rationale for Peripheral Fluid-Based Alzheimer’s Disease Biomarkers
  • 6.3. Metabolomics to Identify Alzheimer’s Disease Biomarkers
  • 6.4. Other Body Fluids as a Sample Sources of Alzheimer’s Disease Biomarkers
  • 6.5. Longitudinal Assessment of Peripheral Blood-Based Alzheimer’s Disease Biomarkers
  • 6.6. Interrelationship of CSF, Neuroimaging, and Peripheral Blood-Based Alzheimer’s Disease Biomarkers
  • 6.7. Potential Challenges in Developing Blood-Based Alzheimer’s Disease Biomarkers
  • 6.8. Performance of Blood-Based Biomarkers in Assessing Drug Efficacy in Alzheimer’s Disease Clinical Trials
  • 6.9. Conclusions
• Chapter 7: Cell-Based Alzheimer’s Disease Biomarkers
  • Summary
  • 7.1. Background
  • 7.2. Rationale for Cell-Based Alzheimer’s Disease Biomarkers
  • 7.3. Blood Cell-Based Alzheimer’s Disease Biomarkers
  • 7.4. Systemic Pathophysiology of Alzheimer’s Disease in Skin Fibroblasts
  • 7.5. Skin Fibroblast-Based Alzheimer’s Disease Biomarkers
  • 7.6. Ocular Biomarkers in Alzheimer’s Disease
  • 7.7. Other Peripheral Cell-Based Biomarkers for Alzheimer’s Disease
  • 7.8. Future Approaches to Cell-Based Alzheimer’s Disease Peripheral Biomarker Discovery
  • 7.9. Advantages and Disadvantages of Cell-Based Alzheimer’s Disease Biomarkers
  • 7.10. Conclusions
• Index